Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus HYDELTRA TBA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus HYDELTRA TBA.
CORTIFOAM vs HYDELTRA-TBA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Prednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene transcription to suppress inflammation, immune response, and adrenal function.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
20-40 mg intramuscularly every 3 weeks; for intra-articular use: 20-40 mg per large joint, 10-20 mg per medium joint, 4-10 mg per small joint.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Plasma t1/2 ~2.5-3.5 hours. Duration of adrenal suppression may persist for 24-48 hours.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily renal (80-90% as inactive metabolites and unchanged drug). Biliary excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid